Bayer Healthcare says it will aggressively expand its biotech pipeline in the year ahead, concentrating on new development pacts in cardiology, hematology and oncology. The company is looking to strike new deals similar to the ones it has reached with Nuvelo and Onyx Pharmaceuticals. Hans Bishop, the former senior v.p. for Chiron's UK operations, will likely head up many of these new ventures. Bishop is expected to be tapped as the next president of the company's hematology and cardiology business after Joe Akers retires.
- here's the report on Bayer from the East Bay Business Journal
Bayer sells subsidiary in €1.2B deal. Report
Bayer Schering outlines global R&D restructuring. Report
Bayer outbids Merck KGaA for Schering. Report